Abstract | BACKGROUND: METHODS: The compounds were evaluated by intraperitoneal and intranasal infection routes using multiple doses of each agent, with single doses of compound given 24 h after virus challenge. RESULTS: By intraperitoneal route, cidofovir protected mice from mortality at 40, 80 and 160 mg/kg, whereas cyclic HPMPC was similarly protective only at 160 mg/kg. By intranasal route, cidofovir was active down to 5 mg/kg, compared to cyclic HPMPC efficacy at 20 and 40 mg/kg. Intraperitoneal doses of 40, 80 and 160 mg/kg cidofovir significantly reduced mortality from vaccinia virus infections, compared to doses of 80 and 160 mg/kg cyclic HPMPC. Intranasal treatment with cidofovir at 5-40 mg/kg was comparably effective to cyclic HPMPC doses of 20 and 40 mg/kg in vaccinia virus infections. Active doses significantly reduced lung virus titers and lung consolidation. Overall, the potency of cyclic HPMPC was about 4 times less than that of cidofovir. CONCLUSIONS:
|
Authors | Donald F Smee, Kevin W Bailey, Robert W Sidwell |
Journal | Chemotherapy
(Chemotherapy)
Vol. 49
Issue 3
Pg. 126-31
(Jun 2003)
ISSN: 0009-3157 [Print] Switzerland |
PMID | 12815205
(Publication Type: Comparative Study, Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Copyright | Copyright 2003 S. Karger AG, Basel |
Chemical References |
- Antiviral Agents
- Organophosphonates
- Organophosphorus Compounds
- cyclic-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine
- Cytosine
- Cidofovir
|
Topics |
- Administration, Intranasal
- Animals
- Antiviral Agents
(administration & dosage, pharmacology)
- Cidofovir
- Cowpox
(drug therapy, veterinary)
- Cytosine
(administration & dosage, analogs & derivatives, pharmacology)
- Female
- Infusions, Parenteral
- Liver
(drug effects, pathology)
- Lung Diseases
(drug therapy, veterinary, virology)
- Mice
- Mice, Inbred BALB C
- Organophosphonates
- Organophosphorus Compounds
(administration & dosage, pharmacology)
- Vaccinia
(drug therapy, veterinary)
|